Industry news that matters to you.  Learn more

Archives for October 2011

Biomarker Commons Named Personalized Medicine World Conference (PMWC) Media Partner

The 4th Personalized Medicine World Conference (PMWC) 2012 will be held in Mountain View, California from January 23rd-24th at Silicon Valley’s Computer History Museum. PMWC brings together the thought-leaders in business, government, healthcare-delivery, research and technology for one information-rich, two-day conference.

Drug Safety, Efficacy, and Potential New Cancer Biomarker Predicted by NextBio

New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation. The unique capabilities of NextBio to search and make discoveries, not possible by other methods, from the massive amounts of genomic data increasingly available in the public domain is the subject of two poster presentations at the American Society of Human Genetics/International Congress of Human Genetics meeting in Montreal, October 11-15.

KGI Professor Links MicroRNA Gene to Aggressive Skin Cancer

A certain microRNA gene, miR-34b, could be a useful biomarker in early diagnosis of the most lethal forms of melanoma, according to new research published by KGI Professor Animesh Ray and his research collaborators.

Exonhit Enters into Research Agreement with Pfizer to Identify Alzheimer’s Disease Biomarkers

Exonhit yesterday announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray (GWSA) platform.

Oryzon to Launch its First Product, GynEC Dx, a Non-invasive Test for the Detection of Endometrial Cancer

The outcome of the clinical trial for GynEC-DX, Oryzon’s first product, was presented recently at the 17th Biennial Meeting of the European Society for Gynaecological Oncology (ESGO) held in Milano (Italy). GynEC-DX, is a new diagnostic test for the early detection of endometrial cancer developed jointly with Reig Jofré Laboratories and expected to be launched on the Spanish market by 1Q-2012. According to the conclusions of this multi-centric double blind prospective clinical trial conducted in 16 Spanish hospitals under the supervision of Dr. Jordi Ponce, at Bellvitge Hospital, and Dr. Antonio Gil, at the Vall d’Hebron Universitary Hospital in Barcelona, GynEC-DX allows to rule out the presence of tumour in 97% of cases through a sample of uterine aspirate, thus allowing a better assessment of whether further analysis, as i.e. histeroscòpies, are indicated.